Greenwich LifeSciences Provides Update on Financing Strategy
Rhea-AI Summary
Greenwich LifeSciences (Nasdaq: GLSI) provided a financing update for Q1 2026 related to its Phase III trial FLAMINGO-01 and investigational immunotherapy GLSI-100.
The company said its ATM program sold common stock into the market and raised more than the company's Q1 2026 cash burn, resulting in an approximate cash balance of $10.5 million as of March 31, 2026; these figures are preliminary and unaudited.
AI-generated analysis. Not financial advice.
Positive
- ATM sales exceeded Q1 2026 cash burn
- Q1 2026 cash balance of approximately $10.5 million as of March 31, 2026
Negative
- Preliminary unaudited financial figures are subject to change following Q1 2026 review
News Market Reaction – GLSI
On the day this news was published, GLSI declined 5.35%, reflecting a notable negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $20M from the company's valuation, bringing the market cap to $361.19M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GLSI gained 6.63% while peers showed mixed single-digit moves (e.g., CHRS +2.40%, CLYM +3.35%, ACOG -0.17%). Momentum scanner only flagged CHRS and AGEN with ~5–6% upside, supporting a more stock-specific backdrop.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Patent expansion update | Positive | +2.2% | Patent claims tied to FLAMINGO‑01 data potentially doubling GP2 market. |
| Mar 19 | New trial sites | Positive | -3.1% | City of Hope network added, expanding FLAMINGO‑01 sites and coverage. |
| Mar 18 | Conference abstracts | Positive | -11.1% | AACR posters accepted with DTH immune data and Phase III design update. |
| Mar 17 | Recurrence data update | Positive | +6.8% | Open-label arm showed markedly reduced recurrence rate vs Katherine study. |
| Mar 16 | Commercial supply approval | Positive | +8.4% | FDA approved first commercial GP2 lot for FLAMINGO‑01 and site supply. |
Recent GLSI news has often been positive, but price reactions have been mixed, with both sharp gains and notable selloffs on clinically focused updates.
Over the last month, GLSI has reported multiple FLAMINGO-01 and GLSI-100 milestones, including FDA approval of the first commercial GP2 lot and supply to ~40 U.S. sites on Mar 16, followed by strong positive price moves. Subsequent clinical and conference updates on recurrence reduction and AACR data saw both gains and pullbacks. A patent update on Apr 07 modestly lifted the stock. Today’s financing update fits into a pattern of funding the Phase III program while advancing trial and IP progress.
Market Pulse Summary
The stock moved -5.3% in the session following this news. A negative reaction despite improved liquidity would fit GLSI’s history of volatility around news, where positive clinical and operational updates sometimes preceded selloffs. The company reported a Q3 2025 net loss of $4,151,845 and highlighted substantial doubt about going concern, making dilution-sensitive investors cautious even as Q1 2026 cash reached about $10.5 million. Prior events show both rallies and pullbacks around Phase III and IP milestones, suggesting sentiment can quickly reverse.
Key Terms
atm financing vehicle financial
immunotherapy medical
fast track regulatory
AI-generated analysis. Not financial advice.
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its financing strategy.
The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through our ATM for Q1 2026 exceeded the Company's Q1 2026 cash burn rate, leading to a Q1 2026 cash balance of approximately
About FLAMINGO-01 Open Label Phase III Data
More than 1,000 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.
- In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70
-80% reduction in recurrence rate. - This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to
80% compared to a 20-50% reduction in recurrence rate by other approved products. - The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.
About GLSI-100 Phase IIb Study
In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an
80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.- The PIS elicited a potent immune response as measured by local skin tests and immunological assays.
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides
For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
